130 related articles for article (PubMed ID: 26864592)
1. Vismodegib and Physeal Closure in a Pediatric Patient.
Lucas JT; Wright KD
Pediatr Blood Cancer; 2016 Nov; 63(11):2058. PubMed ID: 26864592
[No Abstract] [Full Text] [Related]
2. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study.
Gajjar A; Stewart CF; Ellison DW; Kaste S; Kun LE; Packer RJ; Goldman S; Chintagumpala M; Wallace D; Takebe N; Boyett JM; Gilbertson RJ; Curran T
Clin Cancer Res; 2013 Nov; 19(22):6305-12. PubMed ID: 24077351
[TBL] [Abstract][Full Text] [Related]
3. Poly(2-oxazoline) nanoparticle delivery enhances the therapeutic potential of vismodegib for medulloblastoma by improving CNS pharmacokinetics and reducing systemic toxicity.
Hwang D; Dismuke T; Tikunov A; Rosen EP; Kagel JR; Ramsey JD; Lim C; Zamboni W; Kabanov AV; Gershon TR; Sokolsky-Papkov PhD M
Nanomedicine; 2021 Feb; 32():102345. PubMed ID: 33259959
[TBL] [Abstract][Full Text] [Related]
4. Early and persisting response to vismodegib in a patient with bone metastasizing medulloblastoma.
Asklund T; Henriksson R; Axelsson J; Bergström Å; Kasper M; Ögren M; Toftgård R; Riklund KÅ
Acta Oncol; 2013 May; 52(4):862-6. PubMed ID: 23013267
[No Abstract] [Full Text] [Related]
5. Possible mechanisms and biomarkers of resistance to vismodegib in SHH medulloblastoma.
Roesler R; de Farias CB; Brunetto AT; Gregianin L; Jaeger M; Nör C; Thomaz A
Neuro Oncol; 2022 Jul; 24(7):1210-1211. PubMed ID: 35552442
[No Abstract] [Full Text] [Related]
6. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.
Li Y; Song Q; Day BW
Acta Neuropathol Commun; 2019 Jul; 7(1):123. PubMed ID: 31362788
[TBL] [Abstract][Full Text] [Related]
7. Prolonged response to vismodegib in a patient with systemic medulloblastoma metastases.
Climans SA; Macdonald DR; Sutherland DE; Mason WP
BMJ Case Rep; 2020 Oct; 13(10):. PubMed ID: 33122230
[TBL] [Abstract][Full Text] [Related]
8. PTEN loss mitigates the response of medulloblastoma to Hedgehog pathway inhibition.
Metcalfe C; Alicke B; Crow A; Lamoureux M; Dijkgraaf GJ; Peale F; Gould SE; de Sauvage FJ
Cancer Res; 2013 Dec; 73(23):7034-42. PubMed ID: 24154871
[TBL] [Abstract][Full Text] [Related]
9. SHH inhibitors for the treatment of medulloblastoma.
Samkari A; White J; Packer R
Expert Rev Neurother; 2015; 15(7):763-70. PubMed ID: 26027634
[TBL] [Abstract][Full Text] [Related]
10. Targeted Therapy Makes Inroads in Medulloblastoma.
Schmidt C
J Natl Cancer Inst; 2015 Nov; 107(11):djv353. PubMed ID: 26538622
[No Abstract] [Full Text] [Related]
11. Design, Synthesis, and Structure-Activity Relationship of Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Potent Smoothened Antagonists with in Vivo Activity.
Lu W; Liu Y; Ma H; Zheng J; Tian S; Sun Z; Luo L; Li J; Zhang H; Yang ZJ; Zhang X
ACS Chem Neurosci; 2017 Sep; 8(9):1980-1994. PubMed ID: 28618224
[TBL] [Abstract][Full Text] [Related]
12. New-Onset Congestive Heart Failure in a Patient on Vismodegib.
Huizenga T; Newsom E; Fakhouri T; Kado J
Dermatol Surg; 2015 Nov; 41(11):1329-32. PubMed ID: 26458043
[No Abstract] [Full Text] [Related]
13. Persistent alopecia induced by vismodegib.
Alkeraye S; Maire C; Desmedt E; Templier C; Mortier L
Br J Dermatol; 2015 Jun; 172(6):1671-1672. PubMed ID: 25546344
[No Abstract] [Full Text] [Related]
14. Acute pancreatitis after vismodegib for basal cell carcinoma: a causal relation?
Velter C; Blanc J; Robert C
Eur J Cancer; 2019 Sep; 118():67-69. PubMed ID: 31325874
[No Abstract] [Full Text] [Related]
15. Reversible cutaneous side effects of vismodegib treatment.
Kwong B; Danial C; Liu A; Chun KA; Chang AL
Cutis; 2017 Mar; 99(3):E19-E20. PubMed ID: 28398426
[No Abstract] [Full Text] [Related]
16. Four-year experience with vismodegib hedgehog inhibitor therapy.
Simone PD; Schwarz JM; Strasswimmer JM
J Am Acad Dermatol; 2016 Jun; 74(6):1264-5. PubMed ID: 27185433
[No Abstract] [Full Text] [Related]
17. Drug reaction with eosinophilia and systemic symptoms in metastatic basal cell carcinoma treated with vismodegib.
Thomas CL; Arasaratnam M; Carlos G; Parasyn A; Baumgart KW; Fernandez-Penas P; Marx G
Australas J Dermatol; 2017 Feb; 58(1):69-70. PubMed ID: 28195319
[No Abstract] [Full Text] [Related]
18. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449.
Rudin CM; Hann CL; Laterra J; Yauch RL; Callahan CA; Fu L; Holcomb T; Stinson J; Gould SE; Coleman B; LoRusso PM; Von Hoff DD; de Sauvage FJ; Low JA
N Engl J Med; 2009 Sep; 361(12):1173-8. PubMed ID: 19726761
[TBL] [Abstract][Full Text] [Related]
19. Report of cutaneous side effects of vismodegib treatment.
Caplash G; Curragh DS; Halliday L; Huilgol SC; Selva D
Clin Exp Ophthalmol; 2020 Jan; 48(1):123-125. PubMed ID: 31569297
[No Abstract] [Full Text] [Related]
20. Cannabis for Vismodegib-Related Muscle Cramps in a Patient With Advanced Basal Cell Carcinoma.
Kutiel TS; Vornicova O; Bar-Sela G
J Pain Symptom Manage; 2018 May; 55(5):e1-e2. PubMed ID: 29454899
[No Abstract] [Full Text] [Related]
[Next] [New Search]
